ABC-201

Endometriosis

ABC-201 offers a novel first-in-class treatment approach for endometriosis, addressing a significant global unmet need.

300M

Patients worldwide

No therapeutic treatment

$ 5•4 B

Drugs Market by 2034

Abcely is shaping a pipeline designed to unlock new therapeutic and market opportunities.

Evidence

  • Target X (only disclosed under CDA)
  • Specifically expressed in endometriosis at all stages
  • Never been described in this indication (first-in-class)
  • Target involved in the I&I processes controlling the development of EDM
  • Promising in vitro and in vivo efficacy studies on going

Opportunity

Engage monocytes, macrophages and granulocytes via CD89 receptor and T reg Given the chronic nature of endometriosis and the limitations of current treatments, there is a significant opportunity for innovation in developing novel non-hormonal targeted therapies to improve treatment efficacy and quality of life.

The announcement of a cancer diagnosis is a tsunami that stops a life in its tracks, leaving indelible scars and even shattering it completely. Treatment offers repair and reconstruction, healing the body and restoring its integrity. Treatment through remission and healing gives a second chance at life, which takes on an enhanced, unprecedented and new value that every patient feels after being so afraid of losing it.

The ABCELY logo was inspired by the Japanese tradition of ceramic repair, which, instead of hiding fractures and scars, sublimates them by highlighting them in gold, creating a work of art of immense value while restoring its original functionality. Life is never the same after such an experience, both in body and soul. With humility, our logo seeks to symbolize a life rebuilt and sublimated after such a devastating illness.